Arvinas to Participate in Upcoming Virtual Investor Conferences

NEW HAVEN, Conn., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming virtual investor conferences:

Citi 16th Annual BioPharma Virtual Conference on Thursday, September 9, 2021. John Houston, Ph.D., President and Chief Executive Officer, and Ron Peck, M.D., Chief Medical Officer, will participate in a fireside chat at 9:45 a.m. ET. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.

2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021. Sean Cassidy, Chief Financial Officer, and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at 9:20 a.m. ET. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.

About Arvinas
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has three clinical-stage programs: ARV-110 and ARV-766 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.

Contacts for Arvinas

Investors
Will O’Connor, Stern Investor Relations
[email protected]

Media
Kirsten Owens, Arvinas Communications
[email protected]

You May Also Be Interested In

• New Crypto Presale Pepeto Reveals Funds Update While Ethereum Price Prediction Targets $10,000
• Basilea reports strong 2026 half-year results and raises full-year guidance; fosmanogepix phase 3 program on track
• Coloplast A/S - Interim Financial Report, 9M 2025/26